In the Philippines, haematological cancers — including multiple myeloma, CML, and ITP — affect thousands of Filipino patients annually. Brand Velcade, Revlimid, and Zytiga pricing in Philippine private hospitals is completely unaffordable for most patients, making generic Bortenat, Lenalid, and Abiranamo from Unnati Pharmax genuinely life-saving access solutions. Manila's St Luke's, Makati Medical Center, and Philippine General Hospital oncology departments increasingly work with affordable generic suppliers. In South Africa, medical aid schemes are under severe cost pressure from escalating oncology drug costs — generic anti-cancer medicines allow private South African oncologists to provide modern cancer treatment while managing scheme costs sustainably. In Singapore and Australia, self-funding patients and those with partial coverage save thousands of dollars monthly through generic access without compromising clinical outcomes.
Complete documentation for all products — WHO-GMP certificates, certificates of analysis, manufacturer authorisations. DHL/FedEx shipping with tracking. Visit medshopy.com or WhatsApp +91 82650 41513.
How does the cancer medicine affordability crisis differ between the Philippines, South Africa, and Singapore?
Complete documentation for all products — WHO-GMP certificates, certificates of analysis, manufacturer authorisations. DHL/FedEx shipping with tracking. Visit medshopy.com or WhatsApp +91 82650 41513.
How does the cancer medicine affordability crisis differ between the Philippines, South Africa, and Singapore?Each market faces the affordability crisis differently. In the Philippines, the majority of the population is uninsured or underinsured — PhilHealth covers basic services but specialty oncology drugs like Bortezomib or Lenalidomide are largely out-of-pocket at brand prices completely unaffordable for most Filipino families. This creates a stark binary: those who can afford private hospital care face ruinous brand drug costs, while many patients simply go without treatment. In South Africa, the two-tier public/private divide means public sector patients access government-negotiated drug prices through provincial hospitals, but private medical aid patients face branded pricing that is rapidly depleting scheme reserves — driving medical aids to increasingly consider generic substitution. Singapore has high per-capita wealth but equally high brand drug costs, and while government subsidies help for citizens, Permanent Residents and employment pass holders face substantially higher co-payments or self-funding burdens for expensive oncology drugs. Affordable generic access from Unnati Pharmax serves meaningful patient populations in all three contexts.
